Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jonathan W Riess
City of Hope Comprehensive Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Stanford Cancer Institute Palo Alto
Palo Alto, California, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- Uchealth University of Colorado Hospital
Aurora, Colorado, United States
- Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
- Emory Saint Joseph'S Hospital
Atlanta, Georgia, United States
- Emory University Hospital Midtown
Atlanta, Georgia, United States
- Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Brigham and Women'S Hospital
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- Duke Cancer Center Cary
Cary, North Carolina, United States
- Duke University Medical Center
Durham, North Carolina, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 May 2016
- Primary completion
- 30 Jun 2027
- Completion
- 30 Jun 2027
- Last update posted
- 8 Jul 2026
- Registered enrollment
- 138
- Registry id
- NCT02496663
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.